
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
MRCG | Derived | EUR | Real-time | |
MRCG | Xetra | EUR | Delayed | |
MRKd | BATS Europe | EUR | Delayed | |
MKKGY | OTC Markets | USD | Delayed | |
0O14 | London | EUR | Real-time | |
MRCG | Milan | EUR | Real-time | |
MRCG | Frankfurt | EUR | Delayed | |
MRCG | TradeGate | EUR | Delayed |
Merck KGaA operates as a science and technology company in Germany. The company’s Life Science segment offers a range of products, including reagents, consumable, devices, instruments, software, and services for scientific discovery, as well as provides lab water instruments, consumables and services, microbiology and biomonitoring, products, test assays, analytical reagents, and flow cytometry kits and instruments for pharma and biotech, industrial and testing, academics and government, and diagnostic sectors. Its Healthcare segment designs and develops medicines and intelligent devices for treatment of various therapeutics, such as oncology, neurology and immunology, endocrinology, and general medicines. The company’s Electronic segment provides semiconductor solutions, such as semiconductor materials, delivery systems and services, and intermolecular services for semiconductor and polymer removal chemistries applications; and display solutions comprising liquid crystals, OLED and quantum materials, reactive mesogens, photoresist materials, smart antenna, and dynamic liquid crystal glazing products, as well as offers liviFlex, a flexible platform, which offers a range of display materials. This segment also provides surface solution, such as cosmetics, effect pigments, and functional solutions; architecture solutions, including switchable windows; and automotive solutions. In addition, it has strategic alliances with Pfizer Inc. and GlaxoSmihKline plc to develop and commercialize active ingredients in immune-oncology; in-licensing agreement with Debiopharm International SA for developing drug candidates for the treatment of head and neck cancer; and out-licensing agreement with MoonLake Immunotherapeutics AG for developing a drug candidate for the treatment of inflammatory diseases. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA is a subsidiary of E. Merck Kommanditgesellschaft.
Name | Age | Since | Title |
---|---|---|---|
Wolfgang Buchele | 62 | 2009 | Independent Chairman of Supervisory Board |
Sascha Held | 41 | 2019 | Vice Chair of Supervisory Board |
Alexander Putz | 57 | 2020 | Member of Supervisory Board |
Dietmar Oeter | 57 | 2014 | Independent Member of Supervisory Board |
Peter Emanuel Merck | - | 2019 | Independent Member of Supervisory Board |
Daniel Thelen | - | 2019 | Independent Member of Supervisory Board |
Gabriele Eismann | 62 | 2014 | Independent Member of Supervisory Board |
Christian Raabe | - | 2019 | Independent Member of Supervisory Board |
Michael Kleinemeier | - | 2019 | Independent Member of Supervisory Board |
Anne Lange | - | 2019 | Independent Member of Supervisory Board |
Jürgen Glaser | 61 | 2019 | Independent Member of Supervisory Board |
Simon Thelen | - | 2019 | Independent Member of Supervisory Board |
Helga Rübsamen-Schaeff | 74 | 2014 | Independent Member of Supervisory Board |
Birgit Biermann | 50 | 2022 | Member of Supervisory Board |
Renate Koehler | - | 2019 | Independent Member of Supervisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review